{
    "2021-06-03": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera",
                "features": {
                    "keywords": [
                        "Novartis",
                        "clinically relevant",
                        "improvement",
                        "median overall survival",
                        "NETTER-1",
                        "Lutathera"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Prostate Cancer",
                        "Radioligand Therapy",
                        "Extended Overall Survival",
                        "Four Months"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "177Lu-PSMA-617",
                        "overall survival",
                        "radiographic progression-free survival",
                        "metastatic castration-resistant prostate cancer",
                        "Phase III VISION"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}